Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003450
Status:
COMPLETED
Last Update Posted:
2021-02-02
First Post:
1999-11-01
Brief Title:
Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
Sponsor:
University of Texas Southwestern Medical Center
Organization:
University of Texas Southwestern Medical Center
Study Overview
Official Title:
Phase I Trial of Intraperitoneal Adenoviral p53 Gene Therapy in Patients With Advanced Recurrent or Persistent Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Inserting the p53 gene into a persons cancer cells may improve the bodys ability to fight cancer or make the cancer more sensitive to chemotherapy
PURPOSE Phase I trial to study the effectiveness of gene therapy using the p53 gene in treating patients with advanced recurrent or persistent ovarian cancer or primary peritoneal cavity cancer
PURPOSE Phase I trial to study the effectiveness of gene therapy using the p53 gene in treating patients with advanced recurrent or persistent ovarian cancer or primary peritoneal cavity cancer
Detailed Description:
OBJECTIVES I Determine the maximum tolerated dose and toxicities of intraperitoneal adenoviral p53 gene therapy in patients with advanced recurrent or persistent ovarian carcinoma II Evaluate the vector pharmacokinetics and biologic efficacy of gene transfer gene expression and cell death in these patients III Determine the immunologic response to therapy in these patients
OUTLINE This is a dose escalation study of adenoviral p53 gene therapy Patients undergo removal of ascites if present from the peritoneal cavity followed by a bolus infusion of adenovirus p53 once a week for 3 consecutive weeks followed by a 2 week rest Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity Patients who experience palliative results with at least stable disease may continue treatment weekly without the rest period Cohorts of 3-6 patients are treated at each level of adenovirus p53 The maximum tolerated dose is defined as the dose level below that at which 2 of 6 patients experience dose limiting toxicity Patients who receive the MTD without unacceptable toxicity may continue to receive treatment on a weekly basis
PROJECTED ACCRUAL Approximately 15-20 patients will be accrued over 16-18 months for this study
OUTLINE This is a dose escalation study of adenoviral p53 gene therapy Patients undergo removal of ascites if present from the peritoneal cavity followed by a bolus infusion of adenovirus p53 once a week for 3 consecutive weeks followed by a 2 week rest Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity Patients who experience palliative results with at least stable disease may continue treatment weekly without the rest period Cohorts of 3-6 patients are treated at each level of adenovirus p53 The maximum tolerated dose is defined as the dose level below that at which 2 of 6 patients experience dose limiting toxicity Patients who receive the MTD without unacceptable toxicity may continue to receive treatment on a weekly basis
PROJECTED ACCRUAL Approximately 15-20 patients will be accrued over 16-18 months for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-T97-0096 | None | None | None |
| UTSMC-089733300 | None | None | None |